Stock 512 GRAND PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Grand Pharmaceutical Group Limited

Equities

512

BMG210A71016

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 08:22:53 14/05/2024 am IST 		5-day change 1st Jan Change
5 HKD -1.19% Intraday chart for Grand Pharmaceutical Group Limited +12.95% +23.72%
29/04 Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump MT
27/03 Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 11,223 14,321 24,421 22,930 16,225 17,719 17,719 -
Enterprise Value (EV) 1 11,223 14,321 24,421 22,930 16,225 14,394 17,719 17,719
P/E ratio - - - - - 7.63 x 7.33 x 6.33 x
Yield - - - - 3.04% 6.36% 2.57% 3.16%
Capitalization / Revenue 1.88 x 2.17 x 3.84 x 2.67 x 1.7 x 1.37 x 1.47 x 1.3 x
EV / Revenue 1.88 x 2.17 x 3.84 x 2.67 x 1.7 x 1.37 x 1.47 x 1.3 x
EV / EBITDA - - 1,01,16,064 x 71,24,918 x - - - -
EV / FCF - - - 14.9 x 13.3 x 7.65 x 10.8 x 8.62 x
FCF Yield - - - 6.69% 7.5% 13.1% 9.3% 11.6%
Price to Book - - - 1.71 x 1.14 x 0.94 x 1.01 x 0.89 x
Nbr of stocks (in thousands) 31,34,826 33,77,571 35,49,571 35,49,571 35,27,141 35,01,810 35,01,810 -
Reference price 2 3.580 4.240 6.880 6.460 4.600 5.060 5.060 5.060
Announcement Date 26/03/19 27/03/20 28/04/21 17/03/22 22/03/23 19/03/24 - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 5,958 6,591 6,353 8,598 9,562 10,530 12,055 13,620
EBITDA - - 2,414 3,218 - - - -
EBIT 1 - 1,383 2,127 2,879 2,654 2,549 3,205 3,681
Operating Margin - 20.98% 33.48% 33.48% 27.76% 24.21% 26.59% 27.03%
Earnings before Tax (EBT) 1 - - - - - 2,344 2,988 3,463
Net income 1 - - - - - 1,880 2,445 2,835
Net margin - - - - - 17.85% 20.28% 20.81%
EPS 2 - - - - - 0.5360 0.6900 0.8000
Free Cash Flow 1 - - - 1,534 1,216 2,317 1,648 2,056
FCF margin - - - 17.84% 12.72% 21.85% 13.67% 15.1%
FCF Conversion (EBITDA) - - - 47.67% - - - -
FCF Conversion (Net income) - - - - - 109.04% 67.4% 72.52%
Dividend per Share 2 - - - - 0.1400 0.2600 0.1300 0.1600
Announcement Date 26/03/19 27/03/20 28/04/21 17/03/22 22/03/23 19/03/24 - -
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - 1,534 1,216 2,317 1,648 2,056
ROE (net income / shareholders' equity) - - 18.3% 19.5% 15.1% 12.8% 14% 14%
ROA (Net income/ Total Assets) - - 11.6% 12.6% - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - - 3.770 4.020 4.330 5.030 5.670
Cash Flow per Share - - - - - - - -
Capex 1 373 566 209 472 626 600 800 1,000
Capex / Sales 6.26% 8.59% 3.29% 5.48% 6.55% 5.66% 6.64% 7.34%
Announcement Date 26/03/19 27/03/20 28/04/21 17/03/22 22/03/23 19/03/24 - -
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.06
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GRAND PHARMACEUTICAL GROUP LIMITED Stock Grand Pharmaceutical Group Limited
+23.72% 2.24B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.98% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.34% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.52% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.59% 329B
ABBVIE INC. Stock AbbVie Inc.
+4.07% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.21% 240B
NOVARTIS AG Stock Novartis AG
+9.66% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-6.83% 200B
AMGEN INC. Stock Amgen Inc.
+7.09% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 512 Stock
  4. Financials Grand Pharmaceutical Group Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW